Clinical trialNCT02589847CompletedPhase 2Interventional

Microbiota Restoration Therapy for Recurrent Clostridium Difficile Infection

SponsorRebiotix Inc.Enrollment272Clostridium Difficile Infection

View the registry record on ClinicalTrials.gov

Summary

The lay summary the sponsor registered on ClinicalTrials.gov.

This study will evaluate efficacy and safety information about RBX2660 for the treatment of recurrent Clostridium difficile infection (CDI), and will compare the efficacy of one treatment with RBX2660 versus antibiotic-treated historical controls. Enrolled subjects will receive one treatment consisting of two doses of RBX2660 (microbiota suspension).

clinicaltrials.gov ↗

Investigators

The overall officials registered on this study. Names that resolve to a FindMyKOL profile link to it; the rest are shown as registered.

Arnab Ray, MD
Ochsner Health System
Study Chair
clinicaltrials.gov ↗

A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.

Sites

30 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.

Canada

Facility name not stated
Vancouver, British Columbia, Canada
Facility name not stated
Hamilton, Ontario, Canada

United States

Facility name not stated
Phoenix, Arizona, United States
Facility name not stated
North Little Rock, Arkansas, United States
Facility name not stated
Sacramento, California, United States
Facility name not stated
Bay Pines, Florida, United States
Facility name not stated
Coral Springs, Florida, United States
Facility name not stated
Gainesville, Florida, United States
Facility name not stated
Miami, Florida, United States
Facility name not stated
Idaho Falls, Idaho, United States
Facility name not stated
Chicago, Illinois, United States
Facility name not stated
Maywood, Illinois, United States
Facility name not stated
Indianapolis, Indiana, United States
Facility name not stated
Lafayette, Indiana, United States
Facility name not stated
Lexington, Kentucky, United States
Facility name not stated
Detroit, Michigan, United States
Facility name not stated
Rochester, Minnesota, United States
Facility name not stated
Saint Paul, Minnesota, United States
Facility name not stated
St Louis, Missouri, United States
Facility name not stated
Omaha, Nebraska, United States
Facility name not stated
Flushing, New York, United States
Facility name not stated
Rochester, New York, United States
Facility name not stated
Syracuse, New York, United States
Facility name not stated
The Bronx, New York, United States
Facility name not stated
Fargo, North Dakota, United States
Facility name not stated
Lima, Ohio, United States
Facility name not stated
Jackson, Tennessee, United States
Facility name not stated
Houston, Texas, United States
Facility name not stated
Springfield, Virginia, United States
Facility name not stated
Virginia Beach, Virginia, United States

Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.

Drugs studied

The drug and biological interventions registered on this study, normalized to their RxNorm ingredient where possible.

RBX2660Standard of Care Antibiotics

Linked drugs open the directory filtered to KOLs working with them.clinicaltrials.gov ↗

Registration & key dates

Registry attributes as recorded on the ClinicalTrials.gov study record.

Start: 31 Oct 2015
Primary completion: 30 Jun 2017
Completion: 31 Mar 2019
Last update posted: 26 Mar 2021
Registered enrollment: 272
Registry id: NCT02589847

clinicaltrials.gov ↗

Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 24 Aug 2026. Registry facts are shown as registered by the study sponsor; FindMyKOL does not interpret them.